Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Shanghai Junshi Biosciences Co's Debt-to-Equity or its related term are showing as below:
SHJBF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08 Med: 0.21 Max: 0.69
Current: 0.69
During the past 10 years, the highest Debt-to-Equity Ratio of Shanghai Junshi Biosciences Co was 0.69. The lowest was 0.08. And the median was 0.21.
SHJBF's Debt-to-Equity is ranked worse than 82.38% of 965
companies
in the Biotechnology industry
Industry Median: 0.15
vs SHJBF: 0.69
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Shanghai Junshi Biosciences Co Debt-to-Equity Related Terms
Shanghai Junshi Biosciences Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co Debt-to-Equity Chart
SHJBF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Junshi Biosciences Co Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Shanghai Junshi Biosciences Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co (SHJBF) has a Debt-to-Equity of 0.69 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shanghai Junshi Biosciences Co and its competitors. This is 229% above median its historical median of 0.21. Over the past decade, Shanghai Junshi Biosciences Co's Debt-to-Equity has ranged from 0.08 to 0.69. According to the industry distribution chart, Shanghai Junshi Biosciences Co ranks #795 out of 965 companies in the Biotechnology industry, placing it in the top 82.4%.
Is Shanghai Junshi Biosciences Co's Debt-to-Equity too high?
Shanghai Junshi Biosciences Co's current Debt-to-Equity of 0.69 is 229% above median its 10-year median of 0.21. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.69. The Biotechnology industry median Debt-to-Equity is 0.15. Shanghai Junshi Biosciences Co's value of 0.69 is 360% above this industry median. Based on the distribution chart, Shanghai Junshi Biosciences Co ranks #795 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Junshi Biosciences Co has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Junshi Biosciences Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Junshi Biosciences Co ranks #795 out of 965 companies for Debt-to-Equity. This places Shanghai Junshi Biosciences Co in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Shanghai Junshi Biosciences Co's value of 0.69 is 360% above this benchmark. Historically, Shanghai Junshi Biosciences Co's own Debt-to-Equity has ranged from 0.08 to 0.69 over the past decade. While the company's 10-year median is 0.21 vs. the industry median of 0.15, Shanghai Junshi Biosciences Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Junshi Biosciences Co's current Debt-to-Equity of 0.69 is 360% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shanghai Junshi Biosciences Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Junshi Biosciences Co's current Debt-to-Equity is 0.69, which is 229% above median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Junshi Biosciences Co stock overvalued right now?
Shanghai Junshi Biosciences Co (SHJBF) has a current Debt-to-Equity of 0.69. The stock's GF Value™ is $5.55, compared to a current price of $3.35 — trading 39.6% below its estimated fair value. The current Debt-to-Equity is 0.69, which is 229% above median its 10-year median of 0.21 and 360% above the Biotechnology industry median of 0.15. Shanghai Junshi Biosciences Co's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Shanghai Junshi Biosciences Co (SHJBF), the current Debt-to-Equity is 0.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Junshi Biosciences Co (SHJBF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued.
The current stock price of $3.35 is trading 39.6% below its estimated GF Value™ of $5.55.
Key valuation signals for SHJBF:
Debt-to-Equity: 0.69 (229% above median its 10-year median of 0.21)
GF Value™: $5.55 vs. price of $3.35 (39.6% below fair value)
Industry Position: 360% above the Biotechnology median (#795 of 965)
No single metric tells the full story. See the SHJBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
72GF Score
Get the complete analysis for SHJBF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHJBF has been successfully added to your 
